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Supplementary Methods 
 
Synthesis of 8-nitroguanosine 3',5'-cyclic monophosphate (8-nitro-cGMP).  We 
synthesized 8-nitro-cGMP by two reactions: (i) bromination at the C8 position of the 
guanosine moiety, and (ii) nucleophilic substitution of the bromo group with NO2-.  In brief, 
guanosine 3',5'-cyclic monophosphate (cGMP, 150 mg, 0.4 mmol, ICN Biomedicals) was 
reacted with bromine (0.5 ml; Wako Pure Chemical Industries) in 5 ml of formamide on ice 
for 30 min.  The reaction was terminated by adding 2 ml of aniline.  8-Bromoguanosine 
3',5'-cyclic monophosphate (8-bromo-cGMP) was extracted with water and purified by means 
of HPLC with a preparative reverse-phase column (TSKgel ODS-80Ts, 300 mm long × 21.5 
mm inner diameter; Tosoh) eluted with 3.5 ml min–1 of 0.02% trifluoroacetic acid plus 20% 
methanol monitored at 254 nm.  The yield of 8-bromo-cGMP was 53.4 mg (35.6%).  
8-Bromo-cGMP (35 mg, 0.12 mmol) thus obtained was reacted with sodium nitrite (34.5 mg, 
0.5 mmol) in 1.5 ml of dimethyl sulfoxide containing 23 mM HCl at 70 °C for 5 days.  The 
pH of the solution was adjusted to be 9 by adding 1 M NaOH, after which 2 volumes of 
butanol was added to the solution.  8-Nitro-cGMP was extracted from this solution with 
water and was purified via HPLC, in a manner similar to that used for 8-bromo-cGMP.  The 
yield of 8-nitro-cGMP was 11.1 mg (20.8%): 1H NMR (400 MHz, DMSO-d6): δ: 4.06 (1H, 
ddd, j=4.9, 10, 10 Hz), 4.28 (1H, ddd, J=1.7, 10, 10 Hz), 4.43 (1H, ddd, J=20, 10, 4.9 Hz), 
4.83 (1H, d, J=5.4 Hz), 5.02 (1H, ddd, J=10, 5.4, 1.7 Hz), 6.00 (1H, br s), 6.33 (1H, s), 7.05 
(2H, br s), 11.3 (1H, s); UV/Vis: λmax 253, 275, 390 nm (solvent: methanol); MS (ESI, 
negative): calcd. for C10H11N6O9P ([M-H]–), 389.02; found, 389.10. 
 15N-labeled 8-nitro-cGMP (8-15NO2-cGMP) was synthesized with 15N-labeled sodium 
nitrite (Shoko). 
 
 
Syntheses of 8-nitroguanosine derivatives.  8-Nitroguanosine, 8-nitroguanosine 
5'-monophosphate (8-nitro-GMP), 8-nitroguanosine 5'-diphosphate (8-nitro-GDP, 33), and 
8-nitroguanosine 5'-triphosphate (8-nitro-GTP) were synthesized as reported previously1,2.  
8-Nitroguanine and 8-nitroxanthine were obtained as byproducts during syntheses of 
8-nitroguanosine and 8-nitroxanthosine (34).  RNA containing 8-nitroguanine was prepared 
by reacting yeast RNA (2 mg ml–1 in 0.1 M sodium phosphate buffer, pH 7.4, Wako Pure 
Chemical Industries) with 1.5 mM peroxynitrite.  The purified compounds were identified 
by means of their UV absorption spectra, molecular mass, and NMR spectra.  Note that, 
during the synthesis of these compounds, we found 8-nitro-cGMP to be very stable in solution 
even at low pH, whereas 8-nitroguanosine and its phosphorylated derivatives (e.g., 
8-nitro-GMP, 8-nitro-GDP and 8-nitro-GTP) decayed spontaneously in solution, particularly 
at acidic pH, within a few hours.  8-Nitro-2'-deoxyguanosine (35) and its phosphorylated 
forms were extremely unstable: they decomposed readily via spontaneous depurination within 
1 h, even at neutral pH. 
 
Synthesis of 2'-O-succinyl-8-nitroguanosine-3', 5'-cyclic monophosphate 
(2'-O-succinyl-8-nitro-cGMP, 36).  Aqueous solution of 8-nitro-cGMP (15.7 mg, 0.04 
mmol in 1.5 ml H2O) was added triethylamine (0.177 ml, 1.28 mmol) and succinic anhydride 
(64.0 mg, 0.644 mmol) and stirred at room temperature for 1 h.  The reaction mixture was 
concentrated and lyophilized.  The product was purified by HPLC column (Develosil RP 
AQUEOUS, 250 mm long × 20 mm inner diameter, Nomura Chemical Co., Ltd.) eluted with 
methanol: 0.1% trifluoroacetic acid (30:70) to yield 11.5 mg (59%) of a yellow powder: 1H 
NMR (400 MHz, DMSO-d6): δ: 2.50-2.67 (4H, m), 4.09 (1H, ddd, J=4.6, 9.5 Hz), 4.27 (1H, t, 
J=9.5 Hz), 4.49 (1H, m), 5.21 (1H, dd, J=5.9, 9.5 Hz), 5.93 (1H, d, J=5.9 Hz), 6.49 (1H, s), 
7.11 (2H, br s), 11.4 (1H, s); MS (ESI, negative): calcd. for C14H15N6O12P ([M-H]–), 489.04; 
 
found, 489.74. 
 
Antibody generation.  Mouse monoclonal antibodies that specifically recognized the 
8-nitro-cGMP structure were generated by immunizing BDF1 mice (SLC) with 
8-nitro-cGMP-conjugated bovine serum albumin (BSA, Sigma).  We conjugated 
8-nitro-cGMP to BSA through succinyl coupling between the 2'-OH group of 8-nitro-cGMP 
and lysine residues in BSA.  BSA (3 mg) dissolved in 0.75 ml of 0.1 M 
morpholinoethanesulfonic acid (pH 5.5) was reacted with 2'-O-succinyl-8-nitro-cGMP (1.4 
mg, 2.8 μmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (37) (1.5 mg, 7.8 μmol, 
Dojindo Laboratories) at room temperature for 16 h in the dark.  Reaction mixture was then 
dialyzed against phosphate-buffered saline (PBS) overnight at 4 °C.  We began 
immunization by intraperitoneal injection of an 8-nitro-cGMP-BSA conjugate plus Freund’s 
complete adjuvant, followed by injection of antigen with Freund’s incomplete adjuvant.  
After the antibody titer in the blood increased, the spleen was harvested for preparation of 
splenocytes, which were fused with murine myeloma cells (SP2/0) for production of 
hybridomas.  Cells were fused via polyethylene glycol, and hybridomas were selected by 
incubation in hypoxanthine, aminopterin, and thymidine medium.  Hybridomas were 
screened with an ELISA and then cloned by limited dilution. 
 Among antibody clones generated in this study, we used two clones of monoclonal 
anti-8-nitro-cGMP antibodies, clones 1G6 and 1H7, for immunocytochemistry and 
preparation of immunoaffinity columns.  We also used monoclonal anti-8-nitroguanine 
antibody (clone NO2-52) prepared recently3,4.  Specificities of these antibodies are shown in 
Supplementary Fig. 1a online. 
 The polyclonal anti-8-thioalkoxy (RS)-cGMP antibody was raised in rabbits by 
subcutaneous injection of the 8-RS-cGMP adduct of BSA, which was prepared by reacting 
 
8-nitro-cGMP with BSA, plus Freund’s complete adjuvant.  A booster dose of the same 
antigen plus Freund’s incomplete adjuvant was given four times every 2 weeks.  Putative 
contamination with anti-BSA antibody was eliminated by using a BSA-conjugated HiTrap 
NHS-activated HP column (Amersham Biosciences).  Finally, the IgG fraction was purified 
from antiserum by using Protein A-Sepharose CL-4B gel (Amersham Biosciences). 
 Similar to the protocol used for obtaining anti-8-nitro-cGMP antibodies described above, 
the mouse monoclonal anti-8-RS-cGMP antibody was generated by immunizing BDF1 mice 
with the 8-RS-cGMP adduct of BSA. 
 The specificity of these antibodies was confirmed by means of a competitive ELISA, as 
described below.   
 
Competitive ELISA.  To determine the specificity of the antibodies produced, we used 
competitive ELISA as described previously1.  Briefly, each well of a 96-well microtiter plate 
was coated with 100 μl of the 8-nitro-cGMP-BSA conjugate (5 μg ml–1) or 8-RS-cGMP-BSA 
conjugate (0.5 μg ml–1) in PBS, blocked with 0.5% gelatin, and washed three times with PBS 
containing 0.05% Tween 20 (washing buffer).  Wells were incubated at room temperature 
for 1 h with 0.1 ml of antibodies (0.1 μg ml–1) in the presence or absence of various bases and 
nucleosides dissolved in washing buffer.  The wells were then washed with washing buffer 
three times and reacted with horseradish peroxidase (HRP)-conjugated anti-mouse IgG 
antibody, followed by reaction with o-phenylenediamine dihydrochloride (38).  The reaction 
was terminated by addition of 0.05 ml of 2.0 M sulfuric acid, and absorbance at 490 nm was 
read by using a micro-ELISA plate reader. 
 
HepG2 cell culture.  We used cultured human hepatoma cells (HepG2) to study the effect of 
exogenous NO exposure on 8-nitro-cGMP formation.  Our preliminary study showed that 
 
HepG2 cells cultured under conditions of glucose starvation had more intense 
immunostaining for 8-nitro-cGMP when treated with NO donors such as S-nitrosoglutathione 
(GSNO) and S-nitroso-N-acetyl-D,L-penicillamine (SNAP) than did HepG2 cells that had not 
been glucose starved.  HepG2 cells were cultured, at 37 °C in a humidified 5% CO2 
atmosphere, in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% 
penicillin-streptomycin, 1% nonessential amino acid, and 10% fetal bovine serum (FBS).  
Cells were plated at densities of 3 × 105 cells/chamber in CultureSlides (BD Biosciences).  
For glucose starvation, cells were cultured in DMEM without glucose.  To investigate 
formation of 8-nitro-cGMP via exogenous NO donors, cells were treated for 1 h with 500 μM 
SNAP or GSNO in DMEM without glucose supplemented with 1% nonessential amino acid 
and 10% FBS (glucose-free medium).  FBS, that was dialyzed against 150 mM NaCl, was 
used for glucose-free medium.  Cells were then washed with glucose-free medium, followed 
by further incubation for 2 or 11 h in glucose-free medium.  In some experiments, cells were 
treated with 1 mM L-buthionine sulfoximine (BSO, Sigma) before (12 h), during, and after 
SNAP or GSNO treatment.  Formation of 8-nitro-cGMP was determined 
immunocytochemically as described for RAW 264.7 cell culture. 
 
Immunocytochemistry.  To examine the generation and localization of 8-nitro-cGMP and 
related compounds in the cells, we performed immunocytochemistry with the use of 
anti-8-nitro-cGMP monoclonal antibodies (1G6 or 1H7) prepared as described above, and 
anti-8-nitroguanine antibody (NO2-52)3,4.  Cells plated in CultureSlides and treated as 
described in Methods were washed with PBS and fixed with Zamboni solution (4% 
paraformaldehyde and 10 mM picric acid (39) in 0.1 M phosphate buffer, pH 7.4) at 4 °C for 
7 h.   After three washes with PBS, cells were permeabilized with 0.5% Triton X-100 at 
room temperature for 15 min and washed with PBS.  In some experiments, fixed cells were 
 
treated with trypsin (0.1%, GibcoBRL) or RNaseA (0.1 mg ml–1, Sigma) for 30 min at room 
temperature.  Cells were then washed 3 times with PBS.  To block nonspecific antigenic 
sites, cells were incubated at 4 °C overnight with BlockAce (Dainippon Pharmaceutical).  
Cells were then incubated overnight at 4 °C with the monoclonal antibody (10 µg ml–1) in 
PBS with 10% goat serum, after which they were rinsed three times with PBS and incubated 
for 1 h at room temperature with Cy3-labeled goat anti-mouse IgG antibody (PA43002, 10 µg 
ml–1; Amersham Biosciences) in PBS with 10% goat serum.  Cells were washed with PBS, 
covered with SlowFade Light Antifade Kit (S-7461; Molecular Probes), and examined under 
a fluorescence microscope (excitation at 568 nm; model Eclipse E1000, Nikon).  Images 
were digitized and stored in PICT format by using a Color Chilled 3CCD Camera C5810 
(Hamamatsu Photonics KK).  Image processing and quantification were performed by using 
Adobe Photoshop Elements v.2.0 (Adobe Systems).  To localize anti-8-nitro-cGMP (1G6) 
immunostaining in RAW 264.7 cells, anti-histone H1 antibody (MS-628-P0, NeoMarkers), 
anti-Bip antibody (SPA-827, Stressgene), and anti-Hsp antibody (SC-13966, Santa Cruz 
Biotechnology) were used to stain specifically for the nucleus, ER, and mitochondria, 
respectively.  These antibodies were labeled with ZenonTM Alexa Fluor 488 mouse IgG2a 
labeling kit (green, Invitrogen); 1G6 was labeled with ZenonTM Alexa Fluor 555 mouse IgG1 
labeling kit (red, Invitrogen). 
 
Determination of cellular glutathione (GSH).  We determined cellular GSH levels by 
means of HPLC with a reverse-phase column as described previously5.  Cells were plated in 
24-well cell culture plates at a density of 3 × 105 cells/well and incubated as described above.  
Cells were treated with 70% ethanol, and supernatants obtained after centrifugation (8,000 × g 
for 5 min) were mixed with an equal volume of THIOLYTE monobromobimane reagent 
(Calbiochem, EMD Biosciences) (4 mM in 50 mM sodium N-ethylmorpholine, pH 8.0) and 
 
incubated for 5 min at room temperature in the dark.  Proteins were precipitated with 5% 
trichloroacetic acid and were removed by centrifugation at 6,000 × g for 15 min; supernatants 
were injected onto a reverse-phase column (TSKgel ODS-80Ts, 150 mm long × 4.6 mm 
diameter; Tosoh Co.) and eluted with 10% acetonitrile in 0.25% acetic acid, at a flow rate of 1 
ml min–1.  GSH was detected by using fluorescence (excitation, 394 nm; emission, 480 nm) 
(model 821-FP; JASCO Co.) and was quantified by comparison with external standards.   
 
3-Nitro-L-tyrosine analysis.  Protein-bound 3-nitro-L-tyrosine was measured as an index of 
reactive nitrogen species formation in cells by means of HPLC coupled with electrochemical 
detection (ECD) according to our previous paper1, with modification to improve the 
specificity and sensitivity of detection6.  In brief, RAW 264.7 cells, cultured at a density of 2 
× 107 cells in 100-mm dishes, were stimulated in the absence or presence of 1 mM BSO as 
described in Methods.  In some experiments, cells were treated with 1 μM NS 2028 
(Cayman Chemicals) during stimulation in the presence of BSO.  After stimulation, cells 
were washed three times with PBS and were lysed in RIPA buffer (10 mM Tris-HCl, 1% 
NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, pH 7.4) (0.5 ml/dish).  
Low-molecular-weight compounds including nitrite and nitrate were almost entirely removed 
from the lysates by repeating centrifugation three times, using an ultrafiltration membrane 
(5,000-Da cutoff membrane), with nitrite/nitrate-free RIPA buffer added after each 
centrifugation.  High-molecular-weight fractions were then treated with Pronase 
(Calbiochem) at 56 °C for 24 h to liberate free 3-nitro-L-tyrosine, followed by filtration with a 
5,000-Da cutoff membrane and then HPLC-ECD analysis. 
 HPLC separation was carried out with a reverse-phase column (150 mm long, 3.0 mm 
inner diameter; Eicom Pak SC-5 ODS, Eicom) eluted with 0.4 ml min–1 of 200 mM sodium 
phosphate buffer (pH 3.5) plus 2% acetonitrile and 5 μg ml–1 ethylenediaminetetraacetic acid.  
 
3-Nitro-L-tyrosine was detected electrochemically via an online reductive activation method 
with electrode settings of −600 mV (first cell for reduction) and +100 mV (second cell for 
oxidation) (HTEC-500 and PEC-510; Eicom)1.  In separate experiments, tyrosine levels 
were determined by HPLC with a UV detector (280 nm) to normalize the 3-nitro-L-tyrosine 
level. 
 
cGMP measurement.  The intracellular cGMP concentration was determined by using a 
commercial ELISA kit (cGMP-EIA Biotrak System, GE Healthcare Bioscience).  We first 
examined whether the ELISA kit had cross-reactivity for 8-nitro-cGMP and 8-RS-cGMP 
derivatives.  Authentic 8-nitro-cGMP and 8-RS-cGMPs such as 8-Cys-cGMP and 
8-GS-cGMP had dose-response curves comparable to that obtained for authentic cGMP.  
Thus, we could determine the total cGMP levels by using the kit but we could not 
differentiate cGMP from nitrated and 8-RS-cGMP derivatives.  To avoid degradation of 
cGMP during lysate preparation, we added a PDE inhibitor (10 μM zaprinast, Alexis 
Biochemicals) to the RIPA buffer.  cGMP in the RAW 264.7 cell lysates was then measured 
according to the manufacturer’s instruction. 
 
Permeability of membranes to cGMP derivatives.  Membrane permeability of cGMP 
derivatives was determined by measuring cellular uptake of the derivatives.  RAW 264.7 
cells were harvested by trypsinization and were resuspended in DMEM plus 10% FBS with 
10 μM zaprinast in the absence or presence of 10 or 50 μM cGMP derivatives including 
authentic cGMP, 8-nitro-cGMP, and 8-bromo-cGMP.  Cells (6 × 106 cells/tube) were then 
incubated at room temperature for 30 min with gentle mixing.  After incubation, cells were 
washed twice with PBS containing 10 μM zaprinast, and cell pellets were lysed in 0.2 ml of 
RIPA buffer containing 10 μM zaprinast.  Concentrations in cell lysates were determined by 
 
using a commercial ELISA kit as mentioned above.  The degree of permeability was 
assessed via values obtained by the formula: [(intracellular concentration of cGMPs increased 
after incubation)/(concentration of cGMPs added to the cell culture)] × 100 (%). 
 
Reactions of 8-nitro-cGMP with low-molecular-weight sulfhydryls.  We performed liquid 
chromatography-mass spectrometry (LC-MS) analyses to identify products formed in the 
reaction of 8-nitro-cGMP with low-molecular-weight sulfhydryls including GSH, L-cysteine 
and L-Cys-Gly dipeptide (Cosmo Bio Co.).  8-Nitro-cGMP (10 μM) was incubated with 
sulfhydryls (10 mM) in 100 mM sodium phosphate buffer (pH 7.4) at 37 °C.  After certain 
incubation periods, an aliquot of the reaction solution was taken and analyzed via electrospray 
ionization (ESI)-LC-MS using an LCMS-QP8000α mass spectrometer (Shimadzu).  A 
reverse-phase column (5 μm, 150 mm long, 2 mm inner diameter, STR ODS-II; Shinwa 
Chemical Industries) was eluted with solvent A [0.02% trifluoroacetic acid (TFA) plus 2% 
acetonitrile] and solvent B (0.02% TFA plus 15% acetonitrile) in a linear gradient from 
solvent A to B for 20 min.  Electrospray voltage was 2 kV; capillary temperature was 250 °C.  
Reaction products were detected in the positive mode with a mass range of 400-750.  HPLC 
separations were monitored simultaneously with a UV-VIS spectrometer at 254 and 395 nm 
for detection of the cGMP moiety and the 8-nitro-cGMP moiety, respectively.  In a separate 
experiment, 8-nitro-cGMP (1 mM) was reacted with GSH (100 mM) in 0.5 M Tris-HCl (pH 
8.0) at 37 °C for 1 h.  8-S-Glutathionyl-cGMP (8-GS-cGMP) was purified by means of 
HPLC with a preparative reverse-phase column (TSKgel ODS-80Ts, 300 mm long × 21.5 mm 
inner diameter; Tosoh) eluted with 0.02% trifluoroacetic acid plus 18% methanol monitored at 
254 nm.   
 
8-GS-cGMP characterization.  1H NMR (600 MHz, D2O) δ: 2.10 (1H, dt, J = 7.2, 7.2 Hz, 
 
Glu Hβ), 2.46 (1H, t, J = 7.2 Hz, Glu Hγ), 3.36 (1H, m: Cys Hβ), 3.65 (1H, m: Cys Hβ), 4.00 
(1H, t, J = 7.2 Hz, Glu Hα), 3.91 (2H, s: Gly Hα), 4.12 (1H, m: H4’), 4.25 (1H, dd, J = 9.6, 9.6 
Hz, H5’), 4.43 (1H, ddd, J = 4.2, 9.6, 21.6 Hz), 4.67 (1H, dd, J = 4.8, 7.2 Hz: Cys Hα), 4.79 
(overlapped with residual H2O: H2’), 5.17 (1H, m: H3’), 5.98 (1H, s, H1’); 13C NMR (150 
MHz, D2O) δ: 25.5 (Glu Cβ), 31.0 (Glu Cγ), 35.1 (Cys Cβ), 41.2 (Gly Cα), 52.2 (Glu Cα), 53.1 
(Cys Cα), 67.3 (d, JCP = 6.75 Hz, C5’), 71.4 (d, JCP = 7.95 Hz, C2’), 72.0 (d, JCP = 3.75 Hz, 
C4’), 77.0 (d, JCP = 4.20 Hz, C3’), 92.3 (C1’), 116.5 (C5), 143.9 (C8), 152.8 (C4), 153.8 (C2), 
157.8 (C6), 171.5 (Glu carboxylate), 171.9 (Cys amide-carbonyl), 172.9 (Gly carboxylate), 
174.1 (Glu amide-carbonyl); MS (ESI, positive): calcd. for C20H27N8O13PS ([M+H]+), 651; 
found, 651.  The figure below shows correlation of protons by two-dimensional correlated 
spectroscopy experiments (left panel) and correlations found via heteronuclear multiple bond 
correlation experiments (D2O) (right panel). 
 
 
8-S-Cysteinyl-cGMP (8-Cys-cGMP) characterization.  MS (ESI, positive): calcd. for 
C13H17N6O9PS ([M+H]+), 465; found, 465. 
 
 8-S-Cysteinyl-glycyl-cGMP (8-Cys-Gly-cGMP) characterization.  MS (ESI, positive): 
calcd. for C15H20N7O10PS ([M+H]+), 522; found, 522. 
 
LC-ESI/MS/MS analysis.  LC-ESI/MS/MS was performed with a Varian 1200L 
triple-quadrupole mass spectrometer (Varian) after reverse-phase HPLC on a 50 × 2.1-mm 
inner diameter 2 μm X-PressPak C18S column (Jasco) with a linear 0–100% acetonitrile 
gradient for 5 min in 0.1% aqueous acetic acid at 40 °C.  The total flow rate was 0.15 ml 
min–1; injection volume was 10 μl.  The column effluent was introduced directly into the 
mass spectrometer operated in positive mode under following conditions: collision gas 2.2 
mT argon, drying gas 19 psi nitrogen at 300 °C, nebulizing gas 54 psi nitrogen, scan time 1 s, 
needle voltage 5,000 V, shield voltage 600 V, capillary voltage 30 V, detector voltage 1,800 V.  
The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode.  
Scan parameters are shown in Table 1.  These parameters were determined with the 
Automated MS/MS Breakdown software (Varian) using a stock solution of 8-nitro-cGMP and 
8-Cys-cGMP (10 μg ml–1) in acetonitrile/0.1% aqueous acetic acid (1:1 v/v).  Authentic 
8-nitro-cGMP (1 pmol) or 8-nitro-cGMP formed in the cell lysate (600 fmol equivalent) was 
analyzed by this LC-MS/MS system (results appear in Fig. 3c). 
 
Table 1 Scan parameters for LC-MS/MS 
Analyte Precursor ion, m/z Product ion, m/z Collision energy (V) 
8-Nitro-cGMP 391 197 –14 
8-Cys-cGMP 465 184 –32 
 
 
Nitrite (NO2-) measurement.  We quantified NO2- released from 8-nitro-cGMP during 
denitration by means of an HPLC-flow reactor system, as reported previously7.  
8-Nitro-cGMP (10 µM) was incubated with 10 mM GSH or L-cysteine in 100 mM sodium 
phosphate buffer (pH7.4) at 37 °C.  The reaction solution was applied to a reverse-phase 
HPLC column (4.6 × 30 mm, CA-ODS; Eicom Co.) to remove peptides and proteins in 
solution.  NO2- was eluted with 0.55 ml min–1 of 10 mM sodium acetate buffer (pH 5.5) 
containing 0.1 M NaCl and 0.5 mM diethylenetriaminepentaacetic acid, and Griess reagent 
(0.1 ml min–1) was added via a flow-reactor system.  The diazo compound thus formed was 
detected at 540 nm by using a visible light detector (Eicom Co.) and an integrator (System 
Instruments Co.). 
 We also investigated the release of NO2- from 8-nitro-cGMP incubated with cell lysates.  
RAW 264.7 cells were plated in 6-well plates at a density of 5 × 106 cells/well and were 
incubated at 37 °C for 12 h with DMEM plus 2% FBS and various concentrations of BSO (0, 
0.5, and 1 mM), followed by stimulation for 12 h with lipopolysaccharide (LPS, 10 μg ml–1, 
Sigma) and interferon-γ (IFN-γ, 100 U ml–1, R&D Systems) in DMEM plus 2% FBS with or 
without BSO (0.5 or 1 mM).  Cells were then solubilized in 1 ml of RIPA buffer to obtain 
cell lysates.  We incubated 0.1 mM 8-nitro-cGMP dissolved in 50 μl of reaction buffer (50 
mM Tris-HCl, pH 7.6, 3 mM Nω-monomethyl-L-arginine, Sigma) with 50 μl of the cell lysate 
at 37 °C for 6 h.  The NO2- concentration in the reaction solution was determined by means 
of the HPLC-Griess assay mentioned above.  Simultaneously, electron spin resonance (ESR) 
spin trapping was employed to confirm the origin of the NO2- released: 8-15NO2-cGMP was 
used for this purpose.  A 100-μl aliquot of the same reaction solution containing either 
15NO2-cGMP or 14NO2-cGMP was incubated for 30 min at 37 °C with a complex of iron with 
N-(dithiocarboxy)sarcosine [Fe2+-(DTCS)2] that was prepared by mixing 10 mM iron(II) 
sulfate heptahydrate (Wako Pure Chemical Industries) and 40 mM DTCS disodium salt 
 
(Dojindo Laboratories) in 125 mM sodium acetate buffer (pH 4.0) containing 10 mM ascorbic 
acid.  Under these conditions, NO2- was converted to NO, which was trapped by 
Fe2+-(DTCS)2 to give NO-Fe2+-(DTCS)28.  The formation of NO-Fe2+-( DTCS)2 was 
identified by means of X-band ESR spectroscopy (JES-RE1X; JEOL) using a quartz flat cell 
(inner size, 60 × 10 × 0.31 mm) at room temperature.  Conditions for ESR measurements 
were as follows: modulation amplitude, 0.2 mT; time constant, 0.3 s; sweep time, 4 min; 
microwave power, 20 mW; scanning field, 336 ± 5 mT; receiver gain, 500; microwave 
frequency, 9.454 GHz.  With the present conditions, the 14NO-Fe2+-(DTCS)2 complex 
provided a triplet signal with a g value of 2.045, whereas the 15NO-Fe2+-(DTCS)2 complex 
gave a doublet signal with a g value of 2.045. 
 
Western blotting.  We performed Western blotting analysis to assess expression levels of 
various proteins in cells.  Antibodies used included anti-8-RS-cGMP antibody prepared as 
described earlier; anti-Keap1 (rat monoclonal; ref. 9); anti-activated-VASP (46/50-kDa 
vasodilator-stimulated phosphoprotein) (mouse monoclonal, specific for phosphoserine 239; 
Alexis Biochemicals); anti-VASP (rabbit polyclonal; Alexis Biochemicals); and anti-iNOS 
(rabbit polyclonal; Santa Cruz Biotechnology).  Immunoreactive bands were detected by 
using a chemiluminescence reagent (ECL Plus; GE Healthcare, Amersham Biosciences) with 
a luminescent image analyzer (LAS1000UV mini; Fuji Photo Film Co.). 
 
HPLC-ECD measurement of 8-RS-cGMP adducts.  We developed an HPLC-ECD system 
coupled with immunoaffinity enrichment to determine the formation of 8-RS-cGMP adducts.  
We first analyzed 8-RS-cGMP adduct formation in cells treated with authentic 8-nitro-cGMP.  
In brief, RAW 264.7 cells (2 × 107 cells/100-mm dish) were incubated with 10 μM 
8-nitro-cGMP for 11 h.  Cells were washed twice with PBS and were lysed in 0.5 ml of 
 
RIPA buffer.  The lysate was then treated with Pronase at 56 °C for 24 h, followed by 
filtration with a 5,000-Da cutoff membrane as reported previously1.  In another experiment, 
we performed pronase digestion of Keap1 protein obtained from RAW 264.7 cells (2 × 107 
cells/100-mm dish, 5 dishes) stimulated with LPS and IFN-γ in the presence of BSO by 
means of immunoprecipitation with anti-Keap1 antibody (cf. Methods).   These samples 
were then subjected to immunoaffinity enrichment. 
 Immunoaffinity columns were prepared by using monoclonal anti-8-RS-cGMP antibody 
in a manner similar to that used for preparation of immunoaffinity columns for enrichment of 
8-nitroguanine derivatives as described in Methods. 
 HPLC separation of 8-RS-cGMP adducts was achieved with a reverse-phase column (150 
mm long, 3.0 mm inner diameter; Eicom Pak SC-5 ODS, Eicom) eluted with 0.5 ml min–1 of 
200 mM sodium phosphate buffer (pH 5.0) plus 8% acetonitrile.  8-RS-cGMP derivatives 
(e.g., 8-Cys-cGMP and 8-GS-cGMP) were detected electrochemically with electrode settings 
of +700 mV (first cell) and +850 mV (second cell).  The second cell was used as a detection 
cell.  Under these conditions, detection limits were 50 and 100 fmol/injection for 
8-Cys-cGMP and 8-GS-cGMP, respectively. 
 
Animal experiments.  We performed all animal experiments according to the ethical 
guideline and protocol No. O18-138, approved by the Animal Use and Care Administrative 
Advisory Committee of Kumamoto University. 
 
Vascular organ bath study.  Carotid artery rings (4 mm) from male Sprague Dawley rats 
(350 g body weight; Charles River Laboratories Japan) were connected to a force transducer 
(model AG-621G; Nihon Kohden Co.) for recording isometric force and were placed in organ 
baths at 37 °C filled with 3 ml of Krebs buffer (1.2 mM NaHPO4, 120 mM NaCl, 5.9 mM 
 
KCl, 2.5 mM CaCl2, 15.5 mM NaHCO3, 11.5 mM glucose, pH 7.4) (95% O2 and 5% CO2).  
Concentration-response curves to 8-nitro-cGMP derivatives were obtained for arteries 
precontracted with 0.1 μM phenylephrine.  In some experiments, the endothelium was 
mechanically removed.  Superoxide dismutase (SOD, from bovine erythrocytes; Sigma) or 
tiron (Dojindo Laboratories) was added to the organ baths to investigate the effect of 
superoxide.  We performed similar experiments with aorta rings (4 mm) from wild-type and 
eNOS-deficient mice.  eNOS-deficient mice used in the present study were produced and 
maintained as described elsewhere10. 
 
Phosphorylation of VASP.  To study whether 8-nitro-cGMP can activate cGMP-dependent 
protein kinase (PKG), we analyzed phosphorylation of VASP, a target of PKG, by means of 
Western blotting.  Human uterine smooth muscle cells (Cambrex Bio Science Walkersville, 
Inc) were exposed to 10 μM 8-nitro-cGMP or 8-bromo-cGMP.  In some experiments, cells 
were pretreated with 10 μM 8-(4-chlorophenylthio)-guanosine 3′,5′-cyclic 
monophosphorothioate, Rp isomer (Sigma), a PKG inhibitor, for 30 min before exposure to 
8-nitro-cGMP.  Cells were then harvested in lysis buffer (20 mM Tris-HCl pH 8.0, 0.15 M 
NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene 
glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerol phosphate, 1 mM Na3VO4, and 1 μM 
phenylmethanesulfonyl fluoride).  Aliquots (10 μg of protein each) were subjected to 
SDS-PAGE.  After size separation, proteins were blotted onto PVDF membranes (Millipore), 
which were first probed with anti-activated-VASP antibody (specific for phosphoserine 239) 
and then with HRP-conjugated sheep anti-mouse IgG (Amersham Biosciences).  
Immunoreactive bands were visualized via chemiluminescence with ECL Plus.  After 
reprobing, anti-VASP was used as a primary antibody, after which HRP-conjugated goat 
 
anti-rabbit IgG (Amersham Biosciences) was used as a secondary antibody.   
 
Phosphodiesterase (PDE) assay.  We studied susceptibility of 8-substituted cGMP 
derivatives against PDE activity in vitro.  cGMP (10 μM) or its 8-substituted derivatives (10 
μM) were incubated with PDE1 (1 mU ml–1, from bovine brain; Sigma) in 20 mM Tris-HCl 
(pH 7.4) containing 3 mM magnesium chloride, 15 mM magnesium acetate, 0.03 mM 
calcium chloride, and 1 unit ml–1 calmodulin at 30 °C for 30 min, or with PDE5 (0.2 mU ml–1; 
Chemicon International) in 40 mM Tris-HCl (pH 7.4) containing 15 mM magnesium acetate 
and 0.2 mg ml–1 BSA at 30 °C for 60 min.  After reaction of PDEs with 8-substituted 
derivatives of cGMP, enzymes were inactivated by incubation at 95 °C for 2 min.  cGMP 
derivatives remaining in the reaction buffer were quantified by HPLC using a reverse-phase 
column (TSKgel ODS-80Ts, 150 mm long × 4.6 mm diameter; Tosoh Co.) eluted with 1 ml 
min–1 0.02% TFA plus 10% or 15% methanol.  cGMP derivatives were detected via a UV 
detector at 254 nm.   
 
Superoxide generation measured by ESR spectroscopy.  We used ESR spin trapping to 
examine 8-nitro-cGMP-mediated enhancement of superoxide generation from cytochrome 
P450 reductase and all three isoforms of NOS.  P450 reductase and human recombinant 
NOS isoforms were prepared and purified according to the literature11,12.  Each preparation 
was confirmed as fully active on the basis of NADPH oxidation and L-arginine oxidation to 
form L-citrulline13. 
 We used 5-(2,2-dimethyl-1,3-propoxy cyclophosphoryl)-5-methyl-1-pyrroline N-oxide 
(CYPMPO, Radical Research Co.) as the spin trap14.  ESR spectroscopy data, from an 
X-band ESR spectrometer (JES-RE1X), were acquired after 1 min of incubation of 
8-nitro-cGMP with 0.2 μM enzyme in the presence of 0.2 mM NADPH and 2 mM CYPMPO 
 
in 100 mM sodium phosphate buffer (pH 7.4) at room temperature.  ESR measurement was 
repeated five times, and these spectra were averaged to obtain the signal of CYPMPO-OOH 
(a superoxide adduct).  ESR spectra were recorded at room temperature under the following 
conditions: modulation frequency, 100 kHz; modulation amplitude, 0.1 mT; scanning field, 
336 ± 5 mT; receiver gain, 500; response time, 0.3 s; sweep time, 2 min; microwave power, 
10 mW; and microwave frequency, 9.421 GHz.  CYPMPO-OOH was identified according to 
its hyperfine splitting constants (hfc, mT): aN, aH, aP: 1.37, 1.37, 4.88; 1.35, 1.23, 4.7014 
(diastereomers), and its complete disappearance in the presence of SOD.  We further 
determined formation of the radical intermediate of 8-nitro-cGMP by direct ESR spectroscopy 
without spin trapping.  8-Nitro-cGMP (0.2 mM) was incubated with 0.2 μM P450 reductase 
and 1 mM NADPH in 100 mM potassium phosphate buffer (pH 8.8) that had been purged 
with argon gas before use.  After 7 min of incubation at room temperature, ESR spectra were 
recorded. 
 
Statistical analysis.  All data are expressed as means ± s.d.  Data for each condition were 
acquired from at least three independent experiments.  Statistical analyses were performed 
by using Student’s t-test. 
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Supplementary Figure 1 Competetive ELISA (a) and HPLC-ECD analysis (b-d) of 8-
nitro-cGMP and related compounds. (a) Competitive ELISA for reaction of three clones of 
monoclonal antibodies (NO2-52, 1G6, and 1H7) with the 8-nitro-cGMP-BSA conjugate.
Clone NO2-52 specifically recognized the 8-nitro moiety of the purine base; clone 1G6 was 
relatively specific for 8-nitro-cGMP and had no cross-reactivity with nitrated purines 
including 8-nitroxanthine and 8-nitroguanine.  The third antibody used was clone 1H7, 
which was specific for 8-nitro-cGMP, although a weak cross-reaction was observed with 8-
nitroguanosine.  RNA containing 8-nitroguanine was very weakly reactive with 1G6, but 
1H7 had no cross-reactivity with this RNA.  (b) General analytical procedure for HPLC-
ECD.  Cell lysates were subjected to immunoaffinity enrichment, followed by HPLC 
separation.  8-Nitroguanine derivatives were reduced at the first cell to form 
electrochemically active 8-aminoguanine derivatives, which were detected at the second cell
via the oxidation mode (+250 mV).  The electrochemical response at the second cell was 
monitored.  Right panel shows relationship between reducing cell potential and peak 
response.  The potential of the reducing cell was varied to obtain a reduction potential peak 
response of 8-nitroguanine derivatives.  (c) HPLC-ECD chromatogram of authentic samples 
eluted in the presence of 8% acetonitrile (CH3CN).  Peak 1, 8-nitroxanthine; peak 2, 8-
nitroguanine; peak 3, 8-nitroguanosine; peak 4, 8-nitro-cGMP.  (d) HPLC-UV (upper panel) 
and HPLC-ECD (lower panel) chromatograms of authentic samples eluted in the presence 
of 4% acetonitrile.  UV detection at 254 nm revealed cGMP (peak 5) and 8-oxo-2'-
deoxyguanosine (peak 6) in addition to 8-nitroguanine (peak 2), 8-nitroguanosine (peak 3), 
and 8-nitro-cGMP (peak 4).  However, only 8-nitroguanine derivatives could be detected 
via HPLC-ECD under the current conditions.
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Supplementary Figure 2 Formation of 8-nitro-cGMP in macrophages and its regulation by
GSH and sGC.  (a, b) Formation of 8-nitro-cGMP-related compounds in peritoneal exudate 
macrophages obtained from wild-type mice (a) and iNOS-deficient mice (b) after stimulation 
of cells with IFN-γ (100 U ml–1) plus LPS (10 μg ml–1) for 11 h. (c) Formation of 8-nitro-
cGMP in RAW 264.7 cells.  Cells were treated with 1 mM BSO 12 h before and during (11 h) 
stimulation [IFN-γ (100 U ml–1) plus LPS (10 μg ml–1)].  The intensity of immunostaining with 
anti-8-nitro-cGMP antibody (1G6) was determined as described in Methods.  Levels of 
intracellular GSH ([GSH]i), quantified by HPLC, are given in the lower panel.  (d) 
Intracellular levels of 8-nitro-cGMP in RAW 264.7 cells determined by immunocytochemistry 
with the anti-8-nitro-cGMP antibody (top panel) and by HPLC-ECD (second panel); levels of 
protein-bound 3-nitro-L-tyrosine determined by HPLC-ECD (third panel); and levels of cGMP 
determined by using a commercial ELISA kit (bottom panel).  NS 2028 (1 μM), an sGC 
inhibitor, was added to the culture medium during stimulation.  Details of experimental 
procedures are provided in Supplementary Methods online.  BDL, below the detection limit 
(25 fmol/injection).  Scale bars, 25 μm (a, b, c).  Data are expressed as mean ± s.d. (n=3-5). 
*P < 0.05, **P < 0.01, and ***P < 0.001, compared with controls. 
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Supplementary Figure 3 Formation of 8-nitro-cGMP (a) and protein-8-RS-cGMP adducts (b) in 
HepG2 cells.  HepG2 cells were pretreated with BSO (1 mM) for 12 h or had no pretreatment, 
followed by incubation in glucose-free medium (glucose starvation) with or without 500 μM SNAP 
or GSNO (1 h).  Cells were washed with glucose-free medium and further incubated in glucose-free 
medium for 2 h (total 3 h of glucose starvation) or 11 h (total 12 h of glucose starvation).  (a) 
Immunostaining with anti-8-nitro-cGMP antibody (1G6).  Intracellular GSH concentration ([GSH]i) 
is provided in the bottom panel.  Scale bars, 25 μm.  Data are expressed as mean ± s.d. (n=3).  *P < 
0.05, **P < 0.01, and ***P < 0.001, compared with controls. (b) Formation of protein-8-RS-cGMP
adducts in HepG2 cells.  Cells were pretreated with 1 mM BSO for 12 h or were untreated, followed 
by a 1-h treatment with SNAP (500 μM) or 8-nitro-cGMP (500 μM) in the absence or presence of 
BSO (1 mM) under glucose starvation. Cells were washed with glucose-free medium and further 
incubated in the absence or presence of BSO (1 mM) under glucose starvation for 11 h (total 12 h of 
glucose starvation). Cell lysates were subjected to Western blotting (WB) for 8-RS-cGMP (left 
panel).  S-Guanylated Keap1 was detected in HepG2 cells.  HepG2 cells were treated with various 
reagents in the same manner as in a, except for 8-nitro-cGMP treatment.  In that case, unstarved 
cells (no glucose starvation) were incubated with 8-nitro-cGMP for 12 h before cell lysate 
preparation.  Western blotting data for Keap1 and β-actin are shown.  Whole-cell extracts were also 
subjected to immunoprecipitation (IP) with anti-Keap1 antibody.  Immunoprecipitated proteins were 
further analyzed for 8-RS-cGMP and Keap1 by means of Western blotting.  Relative band intensities 
of S-guanylated Keap1 (Keap1-8-RS-cGMP) vs. total Keap1 are given at the bottom. 
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Supplementary Figure 4 Identification of 8-Cys-cGMP adducts in RAW 264.7 cells.  
Specificities of polyclonal (a) and monoclonal (b) anti-8-RS-cGMP antibodies were 
determined by means of competitive ELISA.  The 8-RS-cGMP adduct of BSA was used as an
antigen.  (c) LC-MS/MS determination of 8-Cys-cGMP.  Fragmentation mass spectrum of the 
8-Cys-cGMP adduct (top panel).  The parent pseudo-molecular ion [M + H]+ was at m/z = 465.  
LC-MS/MS chromatograms (m/z: 465→184) of authentic 8-Cys-cGMP (2.5 pmol, middle 
panel) and of RAW 264.7 cell lysate (2.5 mg of protein) (bottom panel) treated with 10 μM 8-
nitro-cGMP for 11 h, followed by immunoaffinity enrichment, are shown. (d) HPLC-ECD 
identification of 8-Cys-cGMP adduct.  Authentic 8-Cys-cGMP (500 fmol) was detected at a 
retention time of 9.5 min under the present conditions (top panel).  8-Cys-cGMP in cell lysate 
(0.5 mg of protein; same sample as that used for c) could be detected in this HPLC-ECD 
system (middle panel).  Endogenous S-guanylation of Keap1 in stimulated RAW 264.7 cells 
(bottom panel).  Keap1 protein was obtained from stimulated RAW 264.7 cells (5 mg of 
protein) by means of immunoprecipitation with the use of anti-Keap1 antibody.  The protein 
was then digested by pronase, and the digested sample was subjected to immunoaffinity 
enrichment with monoclonal anti-8-RS-cGMP antibody before HPLC-ECD analysis.
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Supplementary Figure 5 Modulation of vascular tone by 8-nitro-cGMP.  (a) Effects of 8-
nitro-cGMP on responses of rat carotid artery rings, with or without endothelium, 
precontracted by phenylephrine.  8-Bromo-cGMP was used as the cGMP analogue.  The left 
panels show results for cumulative addition of 8-nitro-cGMP or 8-bromo-cGMP to organ baths.  
The right panels show vascular responses obtained for one administration of 8-nitro-cGMP or 
8-bromo-cGMP.  (b) Effects of 8-nitro-cGMP and 8-nitroguanosine on vascular tone of rat 
carotid artery rings.  (c) Effects of superoxide scavengers on 8-nitro-cGMP-mediated 
vasoconstriction.  Rat carotid artery rings pretreated with indicated concentrations of SOD or 
tiron were precontracted with phenylephrine, followed by addition of 1 μM 8-nitro-cGMP.  
Data are expressed as mean ± s.d. (n=3).  (d) Effects of 8-nitro-cGMP on vascular tone of 
aortas obtained from wild-type and eNOS-deficient mice. 
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Supplementary Figure 6 Resistance of 8-substituted cGMP derivatives to PDE1 and PDE5 (a) and 
vasorelaxation activities of 8-RS-cGMP adducts (b).  In a, cGMP (10 μM) or its 8-substituted 
derivatives (10 μM) were incubated with PDE1 (1 mU ml–1) at 30 °C for 30 min (left panel), or with 
PDE5 (0.2 mU ml–1) at 30 °C for 60 min (right panel). cGMP derivatives remaining in the reaction 
buffer were quantified by means of HPLC. In b, rat carotid arteries precontracted with phenylephrine 
(0.1 μM) were incubated with indicated concentrations of 8-RS-cGMP adducts.  Changes in vascular 
tone were measured as described in Supplementary Methods online. Data are expressed as mean ±
s.d. (n=3).
Supplementary Table 1  Rate constants for the reaction of 8-nitro-cGMP with sulfhydryls a
Sulfhydryl pKa b Reaction pH k2 (M-1min-1) c
7.4 5.40
9.0 8.14
7.4 1.70
9.0 2.15
a8-Nitro-cGMP (20 µM) was reacted with sulfhydryls (10 mM), except for α1-PI, in 200 mM sodium phosphate 
buffer (pH 6.5 and 7.4) or in 200 mM Tris-HCl buffer (pH 9.0) at 37 °C. For α1-PI, 8-nitro-cGMP (100 µM) was 
reacted with 100 µM α1-PI in 200 mM sodium phosphate buffer (pH 7.4) at 37 °C. 
bData reported by Jencks, W.P. & Regenstein, J. in The Handbook of Biochemistry—Selected Data for Molecular 
Biology (ed. Sober, H.A.) 186 (The Chemical Rubber Co., Cleveland, 1968).
cApparent second-order rate constants were determined from the slope of the plot of incubation time vs log(A – A0), 
where A0 is initial absorbance.
α1-PI 7.4 0.43
L-Cysteine 8.30 6.5 1.54
GSH 8.75 6.5 0.56
